JP2025500459A5 - - Google Patents

Info

Publication number
JP2025500459A5
JP2025500459A5 JP2024538134A JP2024538134A JP2025500459A5 JP 2025500459 A5 JP2025500459 A5 JP 2025500459A5 JP 2024538134 A JP2024538134 A JP 2024538134A JP 2024538134 A JP2024538134 A JP 2024538134A JP 2025500459 A5 JP2025500459 A5 JP 2025500459A5
Authority
JP
Japan
Prior art keywords
fibrosis
compound
pharmaceutical composition
intranasal
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024538134A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025500459A (ja
Filing date
Publication date
Priority claimed from GB2118559.0A external-priority patent/GB2613900B/en
Application filed filed Critical
Publication of JP2025500459A publication Critical patent/JP2025500459A/ja
Publication of JP2025500459A5 publication Critical patent/JP2025500459A5/ja
Pending legal-status Critical Current

Links

JP2024538134A 2021-12-20 2022-12-20 バルプロ酸の新規類似体及びそれを用いた治療方法 Pending JP2025500459A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2118559.0A GB2613900B (en) 2021-12-20 2021-12-20 Novel compounds and methods of use thereof
GB2118559.0 2021-12-20
PCT/GB2022/053318 WO2023118846A1 (en) 2021-12-20 2022-12-20 Novel analogs of valproic acid and methods of medical treatment using the same

Publications (2)

Publication Number Publication Date
JP2025500459A JP2025500459A (ja) 2025-01-09
JP2025500459A5 true JP2025500459A5 (https=) 2025-11-26

Family

ID=84887257

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024538134A Pending JP2025500459A (ja) 2021-12-20 2022-12-20 バルプロ酸の新規類似体及びそれを用いた治療方法

Country Status (11)

Country Link
US (1) US20250066282A1 (https=)
EP (1) EP4452917A1 (https=)
JP (1) JP2025500459A (https=)
KR (1) KR20240152301A (https=)
CN (1) CN118613464A (https=)
AU (1) AU2022422574A1 (https=)
CA (1) CA3242987A1 (https=)
GB (1) GB2613900B (https=)
IL (1) IL313669A (https=)
MX (1) MX2024007654A (https=)
WO (1) WO2023118846A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026068561A1 (en) 2024-09-24 2026-04-02 Cereno Scientific Ab Valproic acid for use in treating pulmonary arterial hypertension
GB2644610A (en) * 2024-09-27 2026-04-22 Cereno Scient Ab New methods
GB2644641A (en) * 2024-09-24 2026-04-29 Cereno Scient Ab New methods
WO2026068552A1 (en) 2024-09-24 2026-04-02 Cereno Scientific Ab Deuterated valproic acid compounds for use in treating pulmonary arterial hypertension

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120071554A1 (en) 2008-10-28 2012-03-22 Liu Julie F Deuterated 2-propylpentanoic acid compounds
US20100143507A1 (en) * 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. Carboxylic acid inhibitors of histone deacetylase, gaba transaminase and sodium channel
GB201417828D0 (en) * 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
CA3018043A1 (en) * 2016-04-08 2017-10-12 Cereno Scientific Ab Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof

Similar Documents

Publication Publication Date Title
JP2025500459A5 (https=)
JP2025090726A5 (https=)
JP2018506563A5 (https=)
Muldoon et al. Comparison between extradural infusion of ropivacaine or bupivacaine for the prevention of postoperative pain after total knee arthroplasty.
JP2017504642A5 (https=)
Nishikawa et al. Attenuation of the pressor response to laryngoscopy and tracheal intubation with intravenous verapamil
JP2015524443A5 (https=)
RU96123712A (ru) Пиразоло- и пирролопиридины
JP2016511260A5 (https=)
JP2020522567A5 (https=)
JP2019528279A5 (https=)
JP2019131544A5 (https=)
JP2022545158A5 (https=)
Mather et al. The effects of adding adrenaline to etidocaine and lignocaine in extradural anaesthesia II: Pharmacokinetics
RU2019116820A (ru) Антагонисты интегрина
JP2018525371A5 (https=)
Milne et al. The haemodynamic effects of intraaortic versus intravenous administration of protamine for reversal of heparin in man
RU2024119718A (ru) Новые аналоги вальпроевой кислоты и способы медикаментозного лечения с их применением
JP2019507167A5 (https=)
MX2022010950A (es) Compuesto triciclico fusionado y uso farmaceutico del mismo.
Schweitzer et al. The effect of atropine on cardiac arrhythmias and conduction. Part 1
土手慶五 et al. E fë: fºj stunning ž-E.
JPWO2023032940A5 (https=)
RU2004136583A (ru) Применение валсартана или его метаболита для ингибирования агрегации тромбоцитов
FI4138881T3 (fi) Koostumus, joka käsittää dnaasi i:n käytettäväksi menetelmässä, jolla estetään aim2-inflammasomin aktivaatio